Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Immuneering (IMRX) Gross Margin (2020 - 2022)

Immuneering's Gross Margin history spans 3 years, with the latest figure at 100.0% for Q4 2022.

  • On a quarterly basis, Gross Margin rose 10877.0% to 100.0% in Q4 2022 year-over-year; TTM through Sep 2023 was 100.0%, a 7199.0% increase, with the full-year FY2022 number at 50.11%, up 555.0% from a year prior.
  • Gross Margin came in at 100.0% for Q4 2022, up from 49.6% in the prior quarter.
  • The five-year high for Gross Margin was 100.0% in Q4 2022, with the low at 8.77% in Q4 2021.
  • Historically, Gross Margin has averaged 47.78% across 3 years, with a median of 50.55% in 2022.
  • Biggest five-year swings in Gross Margin: crashed -3762bps in 2021 and later surged 10877bps in 2022.
  • Year by year, Gross Margin stood at 28.85% in 2020, then plummeted by -130bps to 8.77% in 2021, then surged by 1240bps to 100.0% in 2022.
  • Business Quant data shows Gross Margin for IMRX at 100.0% in Q4 2022, 49.6% in Q3 2022, and 49.23% in Q2 2022.